文献速递白血病

靶向细胞周期与凋亡以克服急性髓系白血病化疗耐药

Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2022-11-18

研究通过全基因组CRISPR敲除筛选发现, AraC代谢及细胞周期停滞调控基因(CDKN2A、CHEK2、TP53)敲除参与急性髓系白血病(AML)对多柔比星联合阿糖胞苷(Dox/AraC)的耐药。在人类AML队列中,CDKN2A低表达与更差的总生存相关,且配对诊断-复发样本中CDKN2A在复发时下调。靶向G1S细胞周期限制点(CDK4/6抑制剂palbociclib和KAT6A抑制剂WM-1119上调CDKN2A)或直接促进凋亡(venetoclax)均与化疗协同,克服细胞周期停滞缺陷介导的耐药。

要点

  • CDKN2A低表达与AML患者更差总生存相关,复发时CDKN2A下调。
  • CDK4/6抑制剂palbociclib和KAT6A抑制剂WM-1119上调CDKN2A并与化疗协同。
  • venetoclax直接促进凋亡,与化疗协同克服细胞周期停滞缺陷介导的耐药。

核心结论

  • 细胞周期停滞缺陷是化疗耐药的临床相关因素,合理设计的联合治疗可增强AML缓解并可能规避化疗耐药。

研究设计与样本

  • 研究类型:全基因组CRISPR敲除筛选结合人类AML细胞系及人类AML队列分析;样本量原文未报告。

主要发现

  • 全基因组CRISPR敲除筛选鉴定出AraC代谢基因及细胞周期停滞调控基因(CDKN2A、CHEK2、TP53)敲除与Dox/AraC耐药相关。
  • 在人类AML队列中,CDKN2A表达降低与更差的总生存相关;配对诊断-复发样本中复发时CDKN2A下调。
  • CDK4/6抑制剂palbociclib和KAT6A抑制剂WM-1119通过上调CDKN2A靶向G1S细胞周期限制点,与化疗协同。
  • venetoclax直接促进凋亡,与化疗显示显著协同,克服细胞周期停滞缺陷介导的耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chemotherapy-resistant acute myeloid leukemia (AML), frequently driven by clonal evolution, has a dismal prognosis. A genome-wide CRISPR knockout screen investigating resistance to doxorubicin and cytarabine (Dox/AraC) in human AML cell lines identified gene knockouts involving AraC metabolism and genes that regulate cell cycle arrest (cyclin dependent kinase inhibitor 2A (CDKN2A), checkpoint kinase 2 (CHEK2) and TP53) as contributing to resistance. In human AML cohorts, reduced expression of CDKN2A conferred inferior overall survival and CDKN2A downregulation occurred at relapse in paired diagnosis-relapse samples, validating its clinical relevance. Therapeutically targeting the G1S cell cycle restriction point (with CDK4/6 inhibitor, palbociclib and KAT6A inhibitor, WM-1119, to upregulate CDKN2A) synergized with chemotherapy. Additionally, direct promotion of apoptosis with venetoclax, showed substantial synergy with chemotherapy, overcoming resistance mediated by impaired cell cycle arrest. Altogether, we identify defective cell cycle arrest as a clinically relevant contributor to chemoresistance and identify rationally designed therapeutic combinations that enhance response in AML, potentially circumventing chemoresistance.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ling VY, Straube J, Godfrey W, et al. Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia. Leukemia. 2022. PMID: 36400926. doi:10.1038/s41375-022-01755-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。